UnknownNot Applicable

HyQvia in Multifocal Motor Neuropathy

Netherlands20 participantsStarted 2016-09

Plain-language summary

Subcutaneous immunoglobulin (SCIG) and recombinant human hyaluronidase (rHuPH20) will be tested in patient witch MMN and currently under maintenance treatment with IVIG for safety, tolerability and efficacy.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age at onset of MMN, 18 - 99 years.
✓. The presence of asymmetrical limb weakness at onset or motor involvement having a motor nerve distribution in at least two peripheral nerve distributions, predominant upper limb involvement, disabling weakness MRC grade 4 or less in at least one muscle.
✓. Decreased or absent tendon reflexes in affected limbs.
✓. Electrophysiological evidence of one site with definite motor conduction block or one site with probable conduction block according to previously defined criteria.
✓. Response to IVIG according to criteria that were described in previous studies.
✓. Stable on IVIG maintenance treatment in the year preceding the study.
✓. Patients have given written informed consent, prior to the study, with the understanding that consent may be withdrawn at any time without prejudice.

Exclusion criteria

✕. Bulbar signs or symptoms.
✕. Upper motor neuron signs (spasticity, hyperreflexia, extensor plantar response).
✕. Sensory symptoms and signs with sensory deficits on examination (except for vibration sense) and abnormal results of sensory nerve conduction studies
✕. Other neuropathies (e.g. diabetic, lead, porphyric or vasculitic neuropathy, chronic inflammatory demyelinating polyneuropathy, Lyme neuroborreliosis, post radiation neuropathy, hereditary neuropathy with liability to pressure palsies, Charcot-Marie-Tooth neuropathies, meningeal carcinomatosis).
✕. Treatment with other immunosuppressive drugs (cyclophosphamide, azathioprine, cyclosporin) in the 6 months preceding the study.
✕. Female patient who is pregnant or breast-feeding or of childbearing potential.
✕. being post-menopausal,
✕. being surgically sterile,

What they're measuring

Safety measured by anamnesis

Timeframe: 1 year

Trial details

NCT IDNCT02885259

SponsorUMC Utrecht

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-12

Contact for this trial

Bas Jongbloed, drs

b.a.jongbloed-2@umcutrecht.nl

View on ClinicalTrials.gov More Multifocal Motor Neuropathy trials